NuVasive (NUVA) Receives a Buy from BTIG

In a report issued on August 9, Ryan Zimmerman from BTIG maintained a Buy rating on NuVasive (NUVAResearch Report), with a price target of $71. The company’s shares closed on Friday at $66.07.

According to, Zimmerman is a 5-star analyst with an average return of 21.7% and a 64.9% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics Corp.

Currently, the analyst consensus on NuVasive is a Moderate Buy with an average price target of $69.86, a 5.7% upside from current levels. In a report issued on July 31, Piper Jaffray also maintained a Buy rating on the stock with a $72 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $72.41 and a one-year low of $43.51. Currently, NuVasive has an average volume of 387.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NuVasive, Inc. engages in the development of minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. It offers cervical and spine fusion surgery, cervical plating, and posterior fixation products. The company was founded by Alexis V. Lukianov on July 21, 1997 and is headquartered in San Diego, CA.